REG - Hutchmed China Ltd - Overseas Regulatory Announcement

HUTCHMED (China)Announcement

28/02/2025 15:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250228:nRSb9421Ya&default-theme=true

RNS Number : 9421Y  Hutchmed (China) Limited  28 February 2025

 

Overseas Regulatory Announcement -
Update on Transaction

 

 

HUTCHMED (China) Limited ("HUTCHMED (https://www.hutch-med.com/) ") notes the
below text, which is from an announcement released to the Stock Exchange of
Hong Kong Limited on February 28, 2025 pursuant to Chapter 14 of the Rules
Governing the Listing of Securities on The Stock Exchange of Hong Kong
Limited. The text relates to the further update on dispatch timing of the
extraordinary general meeting circular that relates to the transaction
described in the announcement dated January 2, 2025, entitled "HUTCHMED
Announces US$608 million Divestment of Non-Core Joint Venture".

 

 

About HUTCHMED

 

HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage,
biopharmaceutical company. It is committed to the discovery and global
development and commercialization of targeted therapies and immunotherapies
for the treatment of cancer and immunological diseases. Since inception it has
focused on bringing drug candidates from in-house discovery to patients around
the world, with its first three medicines marketed in China, the first of
which is also approved in the US, Europe and Japan. For more information,
please visit: www.hutch‑med.com (https://www.hutch-med.com/) or follow us on
LinkedIn (https://www.linkedin.com/company/hutchmed/) .

 

CONTACTS
 Investor Enquiries                                   +852 2121 8200 / ir@hutch-med.com (mailto:ir@hutch-med.com)

 Media Enquiries
 FTI Consulting -                                     +44 20 3727 1030 / HUTCHMED@fticonsulting.com
                                                      (mailto:HUTCHMED@fticonsulting.com)
     Ben Atwell / Alex Shaw                              +44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile)
 Brunswick - Zhou Yi                                  +852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com
                                                      (mailto:HUTCHMED@brunswickgroup.com)

 Panmure Liberum                                      Nominated Advisor and Joint Broker
 Atholl Tweedie / Freddy Crossley / Rupert Dearden    +44 20 7886 2500

 HSBC                                                 Joint Broker
 Simon Alexander / Alina Vaskina / Arnav Kapoor       +44 20 7991 8888

 Cavendish                                            Joint Broker
 Geoff Nash / Nigel Birks                             +44 20 7220 0500

 

 

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong
Limited take no responsibility for the contents of this announcement, make no
representation as to its accuracy or completeness and expressly disclaim any
liability whatsoever for any loss howsoever arising from or in reliance upon
the whole or any part of the contents of this announcement.

 

 

HUTCHMED (China) Limited
和黃醫藥（中國）有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 13)

 

MAJOR TRANSACTION

IN RELATION TO

THE DISPOSAL OF 45% EQUITY INTEREST IN

SHANGHAI HUTCHISON PHARMACEUTICALS LIMITED

 

TIMING OF DISPATCH OF CIRCULAR

 

Reference is made to the announcement of HUTCHMED (China) Limited (the
"Company") dated January 1, 2025 (the "January 1 Announcement") in relation to
the proposed disposal of 45% equity interest in Shanghai Hutchison
Pharmaceuticals Limited. Unless otherwise defined, capitalized terms used in
this announcement shall have the same meanings as those defined in the January
1 Announcement.

 

In the Company's announcement dated January 28, 2025, it was mentioned that
the Circular containing, among other things, (i) further details on the terms
of the Proposed Disposal; and (ii) other information as required under the
Listing Rules together with a notice convening the EGM, was expected to be
dispatched to the Shareholders on or before February 28, 2025.

 

GP Health Service Capital has further informed the Seller that the designation
to the GP Purchaser Fund and the Designated Purchaser is progressing but
additional time is required for them to complete the designation. In view of
this, the Company currently expects that the Circular will be dispatched to
the Shareholders on or before March 31, 2025.

 

The Proposed Disposal is subject to all of the conditions under the Agreements
being satisfied (or, if applicable, waived) and therefore may or may not
become unconditional. If any of the conditions under the Agreements is not
satisfied (or, if applicable, waived), the Proposed Disposal will not proceed.
Shareholders and potential investors are reminded to exercise caution when
dealing in the shares and other securities of the Company.

 

By Order of the Board

Edith Shih
Non-executive Director and Company Secretary

 

Hong Kong, February 28, 2025

 

As at the date of this announcement, the Directors of the Company are:

 

 Chairman and Non-executive Director:  Non-executive Directors:

 Dr Dan ELDAR                          Ms Edith SHIH

                                       Ms Ling YANG

 Executive Directors:

 Dr Weiguo SU                          Independent Non-executive Directors:

 (Chief Executive Officer and          Mr Paul Rutherford CARTER

Chief Scientific Officer)

                                     (Senior Independent Director)
 Mr CHENG Chig Fung, Johnny

                                     Dr Renu BHATIA
 (Chief Financial Officer)

                                       Dr Chaohong HU

                                       Mr Graeme Allan JACK

                                       Professor MOK Shu Kam, Tony

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCTPMITMTATBBA